SCHEMBL607170

SCHEMBL607170

NC(=O)c1ccc2cc3cc4ccccc4cc3cc2c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.70
PLAU P00749 2/20 0.61
CES2 O00748 1/20 0.59
CES1 P23141 1/20 0.59
F2 P00734 1/20 0.55
PLG P00747 1/20 0.55
KLKB1 P03952 1/20 0.55
KLK1 P06870 1/20 0.55
PRSS1 P07477 1/20 0.55
PARP1 P09874 2/20 0.52
ALDH1A1 P00352 3/20 0.50
CYP3A4 P08684 3/20 0.50
HSD17B10 Q99714 3/20 0.50
TDP1 Q9NUW8 3/20 0.50
KDM4E B2RXH2 2/20 0.50
MAPT P10636 2/20 0.50
ALOX15 P16050 2/20 0.50
MEN1 O00255 1/20 0.50
EGFR P00533 1/20 0.50
TP53 P04637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8161748 1.00 LCK (0.70) LCKPLAUCES2CES1F2
SCHEMBL30350858 1.00 LCK (0.70) LCKPLAUCES2CES1F2
SCHEMBL30277311 1.00 LCK (0.70) LCKPLAUCES2CES1F2
Hydrochloric Acid SCHEMBL27922456 0.98 LCK (0.68) LCKPLAUCES2CES1F2
SCHEMBL28074925 0.98 LCK (0.68) LCKPLAUCES2CES1F2
SCHEMBL546633 0.93 CES2 (0.68) LCKPLAUCES2CES1F2
SCHEMBL29462782 0.93 CES2 (0.68) LCKPLAUCES2CES1F2
SCHEMBL26903783 0.93 CES2 (0.68) LCKPLAUCES2CES1F2
Hydrochloric Acid SCHEMBL8358165 0.91 CES2 (0.65) LCKPLAUCES2CES1F2
Hydrochloric Acid SCHEMBL22558829 0.91 CES2 (0.65) LCKPLAUCES2CES1F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210393695-A1 COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES FATE THERAPEUTICS, INC. 2021-12-23 US claimed
CN-109563035-A The crystal form of tetracycline compound and preparation method thereof that 9- amino methyl replaces 山东亨利医药科技有限责任公司 2019-04-02 CN claimed
CN-105008382-B Estra-1, 3,5(10), 16-tetraene-3-carboxamides for the inhibition of 17 β -hydroxysteroid dehydrogenase (AKR 1C 3) 拜耳医药股份公司 2018-01-30 CN claimed
US-20050227266-A1 Biomarker:compound correlations in cancer diagnosis and therapy APPLIED GENOMICS, INC. 2005-10-13 US claimed
WO-2005085863-A2 BIOMARKER: COMPOUND CORRELATIONS IN CANCER DIAGNOSIS AND THERAPY APPLIED GENOMICS, INC. (US) 2005-09-15 WO claimed
US-12419870-B2 Compositions and methods for immune cell modulation in adoptive immunotherapies FATE THERAPEUTICS, INC. (US) 2025-09-23 US disclosed
US-20250215396-A1 COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES FATE THERAPEUTICS, INC. 2025-07-03 US disclosed
CN-120157555-A Preparation method of primary amide compound 浙江工业大学 2025-06-17 CN disclosed
US-12281329-B2 Compositions and methods for immune cell modulation in adoptive immunotherapies FATE THERAPEUTICS, INC. (US) 2025-04-22 US disclosed
US-20250024837-A1 PESTICIDE SYSTEM BANISH, MICHELE 2025-01-23 US disclosed
US-20240263135-A1 COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES FATE THERAPEUTICS, INC. 2024-08-08 US disclosed
CN-118414330-A Naphthalene and quinoline analogs as RXFP1 agonists 百时美施贵宝公司 2024-07-30 CN disclosed
CN-1072172-A Novel 7-replacement-9-substituted-amino-6-demethyl-6-deoxidation tsiklomitsin AMERICAN CYANAMID CO (US) 1993-05-19 CN disclosed
EP-0409957-A4 BIOLOGICAL FLUIDS PURIFICATION SYSTEMS 1993-01-07 EP disclosed
US-5149718-A BIOLOGICAL FLUID PURIFICATION SYSTEM NEW YORK UNIVERSITY (US) 1992-09-22 US disclosed
EP-0426785-A4 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS 1991-11-13 EP disclosed
EP-0426785-A1 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS NEW YORK UNIVERSITY (US) 1991-05-15 EP disclosed
EP-0409957-A1 BIOLOGICAL FLUIDS PURIFICATION SYSTEMS NEW YORK UNIVERSITY (US) 1991-01-30 EP disclosed
WO-1990010438-A1 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS NEW YORK UNIVERSITY (US) 1990-09-20 WO disclosed
WO-1990007876-A1 BIOLOGICAL FLUIDS PURIFICATION SYSTEMS NEW YORK UNIVERSITY (US) 1990-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250024837-A1 PESTICIDE SYSTEM ACHE, PFAS, FPGS LCK 1938/4885PLAU 1246/4885CES2 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.